Research
Effect of two common GVHD prophylaxis regimens on the gut microbiome in a randomized phase 3 trial
Nature · By Jakob Wirbel ·
The Brief
- A prespecified companion study (BMT CTN 1801) analysed the gut microbiome within the randomized phase 3 trial BMT CTN 1703, which compared two common GVHD prophylaxis regimens.
- The source excerpt says microbiome diversity at engraftment did not associate with an outcome, but the sentence is cut off, so the full finding is not available here.
Why it matters
Transplant clinicians choose GVHD prophylaxis regimens partly on their side effects, so evidence on whether these regimens shift the gut microbiome during engraftment is relevant to patient care and microbiome research.
Who’s affected
- transplant clinicians and hematologists
- microbiome researchers
- patients receiving allogeneic stem cell transplants
- BMT CTN 1703
- BMT CTN 1801
- #gvhd
- #microbiome
- #stem cell transplant
- #clinical trial
- #immunosuppression
Nature Medicine, Published online: 12 November 2026; doi:10.1038/s41591-026-04712-z In a prespecified companion study (BMT CTN 1801) of the randomized phase 3 BMT CTN 1703 trial comparing two common GVHD prophylaxis regimens, microbiome diversity at engraftment did not associate…
Timeline
Published online in Nature Medicine
nature.com
Effect of two common GVHD prophylaxis regimens on the gut microbiome in a randomized phase 3 trial